-
ABOUT USAffiliated to SSY Group Limited, Hebei Guangxiang Technology Co., Ltd., is a high-tech enterprise specializing in drug research and technology development.
-
INNOVATIONSSY Group Limited has built a relatively perfect scientific research and innovation system with the synergy between “industry, academia, research and application” based on multi-disciplinary integration and multi-directional combination.
-
SUBORDINATEThe group has decided to establish research institutes in its subsidiaries, Hebei Ghuangxiang Drug Research Institute, Jiangsu Best Medical Material Research Institute, and Hebei Hanlin Biological Research Institute.
-
RECRUITWe actively establish a joint talent cultivation mechanism between schools and enterprises, and currently have over 500 high-level talents in various fields such as drug research, analysis, and clinical practice.
-
CONTACTWe will continue to strengthen innovation-driven development, vigorously promote the integration of production and research, constantly improve the five domains: new drugs, biological drugs, traditional Chinese medicine, generic drugs and APIs.
Big News! Shijiazhuang Sihua Pharmaceutical’s azithromycin injection (0.5g and 0.25g) has received approval for a supplemental drug application, making the company the marketing authorization holder for this product.
Category:
Time：2021-07-03
On June 30, Shijiazhuang Sihua Pharmaceutical Co., Ltd. obtained approval from the National Medical Products Administration for a supplemental drug application concerning injectable azithromycin (0.5g and 0.25g), thereby becoming the marketing authorization holder for this product.
On June 30, Shijiazhuang Sihua Pharmaceutical Co., Ltd. obtained approval from the National Medical Products Administration for a supplemental drug application concerning injectable azithromycin (0.5g and 0.25g), thereby becoming the marketing authorization holder for this product.
It is understood that this product is a lyophilized powder for injection, primarily used to treat various infections caused by susceptible pathogens. Obtaining the lyophilized powder for injection formulation for the first time will help the company diversify its dosage forms, optimize its product mix, accelerate the transformation of its supply-side structure, and further promote its high-quality development.
Keywords:
Recommended News
Share to
SERVICE HOTLINE
Mobile site
E code
Business license